IPCA Laboratories Limited
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
What IPCA files
- Others46
- Investor Meet26
- Important21
- Board Meeting11
- Updates9
- Dividend/Bonus8
Ipca Labs partnered globally with Bhami's Research Lab for novel subcutaneous biologics delivery tech. This targets developing cancer and inflammatory disease treatments. Ipca handles development/commercialization; BRL gets technology transfer milestones and sales royalties.
Ipca Lab has commenced commercial production at its new greenfield Drug Intermediates/API manufacturing facility. Built with a capital outlay of 182 Cr, this operational expansion aims to boost future production and revenue.
Ipca Labs' Tarapur API plant received a US FDA Voluntary Action Indicated (VAI) classification. This confirms the facility is in a minimally acceptable state of compliance with good manufacturing practices, easing concerns about operational disruptions.
Ipca Labs' Tarapur API facility received a US FDA Form 483 with 3 observations post-inspection. The company plans a comprehensive response, emphasizing its commitment to resolving compliance issues and maintaining quality standards.
Company updated on physical share transfer requests for October, submitting a report from its Registrar and Share Transfer Agent. This reflects ongoing compliance with share registry procedures.